Thus, systemic blockade of TGF-β signaling with neutralizing anti-TGF-β1 antibodies has been developed for the treatment of both type 1 diabetic nephropathy (T1DN) and T2DN 10-13. Here, TGFB1 is linked to type 1 diabetes nephropathy.